Nuvalent, Inc. (NUVL)
105.64
+3.19
(+3.11%)
USD |
NASDAQ |
Apr 01, 16:00
105.58
-0.06
(-0.06%)
After-Hours: 20:00
Nuvalent Research and Development Expense (TTM) : 306.97M for Dec. 31, 2025
Research and Development Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| Glaukos Corp. | 150.61M |
| Edgewise Therapeutics, Inc. | 149.30M |
| Cogent Biosciences, Inc. | 265.16M |
| Neurocrine Biosciences, Inc. | 1.016B |
| Arcellx, Inc. | 157.61M |